Willow Club Willow Academy
Articles

UAE Corporate Tax and IFRS Case Study: correction of pre-tax closing balance

This case study considers how a correction of an accounting error may affect UAE Corporate Tax. Where a company was incorporated in 2023, its 31 December 2023 balance sheet may form the bridge into the first Corporate Tax period. If equity instruments were incorrectly carried at cost instead of FVOCI, the error is not only an accounting issue. It may affect the opening balance, the allocation of pre-CT and post-CT value movements, and the availability of transitional relief. The key point is that the corrected 31 December 2023 fair value should be documented and introduced into the comparative analysis, even if 2023 is not formally presented as a comparative year.

Facts

A company was incorporated in the UAE in 2023.

In 2023, management issued a decision approving the accounting treatment of certain financial assets for the current and subsequent reporting periods. According to this decision, the Company elected to account for the relevant equity instruments at fair value through other comprehensive income (“FVOCI”).

However, the Company did not apply this treatment in its accounting records. Instead, the Company recognized the relevant equity financial assets at cost. The audited financial statements for 2023 and 2024 also stated that the Company applied the cost method rather than fair value measurement.

In 2025, the Company identified the 2023 management decision and concluded that the accounting treatment applied in 2023 and 2024 may have been inconsistent with the Company’s accounting policy and with IFRS 9.

The Company is considering correcting the prior treatment in its 2025 financial statements under IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors.

For UAE Corporate Tax purposes, the Company’s balance sheet as at 31 December 2023 is particularly important, because it represents the opening balance position for the first UAE Corporate Tax period, assuming the Company’s first Tax Period starts on 1 January 2024. The question is therefore not only whether the accounting correction can be made, but also how the corrected 2023 closing position should be used for UAE Corporate Tax purposes.

Questions

  1. Can the Company treat the recognition of the relevant equity instruments at cost in 2023 and 2024 as a prior period error under IAS 8?
  2. If the Company corrects the error and recognises the instruments at FVOCI, why does this matter for UAE Corporate Tax?
  3. Should the corrected fair value of the equity instruments as at 31 December 2023 be introduced into the comparative (restatement) analysis, even if the 2025 financial statements formally present only 2024 as the comparative year?
  4. Can the Company rely on the UAE Corporate Tax transitional relief for financial assets if the corrected accounting treatment is FVOCI rather than cost?

Summary

  1. In our view, if the 2023 management decision constituted a valid IFRS 9 FVOCI election made at initial recognition, the Company has a strong basis to treat the use of cost in the 2023 and 2024 financial statements as a prior period error under IAS 8.
  2. This conclusion matters for Corporate Tax because the UAE Corporate Tax system starts from the accounting result and the accounting balance sheet. The accounting correction is therefore not merely a financial reporting matter. It can affect the opening position for the first Corporate Tax period, the timing of taxable gains and losses, the treatment of unrealised movements, and the availability or non-availability of transitional relief.
  3. In particular, the Company should determine and document the corrected fair value of the relevant equity instruments as at 31 December 2023. That date is the bridge between the pre-Corporate Tax period and the first Corporate Tax period, assuming the first Tax Period starts on 1 January 2024. The 31 December 2023 closing balance is, in substance, the opening balance for Corporate Tax purposes.
  4. The Company should therefore include the corrected 31 December 2023 measurement in the comparative (restatement) analysis. This recommendation applies even if the 2025 financial statements formally present only 2024 as the comparative period. Without a corrected 2023 closing balance, the Company may not be able to explain properly which fair value movement belongs to the pre-Corporate Tax period and which belongs to the Corporate Tax period.
  5. However, the same correction also limits the availability of transitional relief. The UAE transitional rules for qualifying financial assets and liabilities are designed for assets and liabilities owned before the first Tax Period and recorded on a historical cost basis. If the correct accounting treatment is FVOCI, the asset is not recorded on a historical cost basis. On that basis, the specific transitional relief for financial assets should not be available.
  6. This is not necessarily adverse in every case, because the corrected fair value balance as at 31 December 2023 may itself protect the pre-Corporate Tax gain by placing it outside the opening Corporate Tax base. But the mechanism is different: the protection comes from the corrected opening accounting balance, not from the transitional relief election for historical-cost assets.

Analysis

  1. The first step is to identify the nature of the financial statements in which the relevant investment is recognised. Since the Company prepares separate financial statements, the starting point is IAS 27.10, which provides that when an entity prepares separate financial statements, it shall account for investments in subsidiaries, joint ventures and associates either:
    1. at cost;
    2. in accordance with IFRS 9; or
    3. using the equity method as described in IAS 28.
  2. Therefore, where the relevant equity instruments represent an investment in a subsidiary, joint venture or associate, the use of cost is not automatically impermissible. IAS 27.10 expressly permits the cost method as one of the available measurement bases in separate financial statements.

    The issue is therefore not simply whether IFRS 9 generally requires equity instruments to be measured at fair value, but which of the IAS 27.10 alternatives the Company validly selected and consistently applied
  3. On the facts provided, the Company’s 2023 management decision appears to have selected the second IAS 27.10 alternative, namely accounting for the relevant equity instruments in accordance with IFRS 9. If so, the Company was not applying the IAS 27.10 cost method. Rather, it elected to bring the investment within the IFRS 9 classification and measurement framework.
  4. Once the Company elected to account for the investment in accordance with IFRS 9, the relevant IFRS 9 rules should have been applied. Under IFRS 9.5.7.5, an entity may, at initial recognition, make an irrevocable election to present in other comprehensive income subsequent changes in the fair value of an investment in an equity instrument, provided that the investment is not held for trading and does not fall within the excluded categories.
  5. Accordingly, if the 2023 management decision was made at initial recognition of the relevant equity instruments and constituted an IFRS 9.5.7.5 FVOCI election, the Company should have recognised the relevant investments at fair value, with subsequent fair value movements presented in OCI. In that case, continuing to carry the instruments at historical cost in 2023 and 2024 would not represent a valid application of the IAS 27.10 cost method. It would represent a failure to apply the measurement basis actually selected by management.
  6. This distinction is important. If the Company had originally selected the IAS 27.10 cost method, then the audited financial statements’ reference to cost could have been consistent with IFRS, at least for separate financial statements. However, if the Company originally selected IFRS 9 FVOCI treatment, the later reference to cost in the audited financial statements would be inconsistent with the Company’s own accounting policy decision.
  7. IFRS 9.B5.2.3 then becomes relevant only after it is established that the Company selected IFRS 9 accounting rather than the IAS 27.10(a) cost method. IFRS 9.B5.2.3 states that all investments in equity instruments and contracts on those instruments must be measured at fair value.

    It also recognises that, in limited circumstances, cost may be an appropriate estimate of fair value. However, this does not convert cost into a separate IFRS 9 accounting policy. It only allows cost to be used as a proxy for fair value where the facts support such a conclusion.
  8. Therefore, the analysis should distinguish between three possible cases:
    1. the Company validly selected the IAS 27.10 cost method in its separate financial statements, in which case cost accounting may be IFRS-compliant;
    2. the Company selected IFRS 9 FVOCI treatment at initial recognition, but subsequently carried the investment at historical cost, in which case the treatment is likely an accounting error; or
    3. the Company selected IFRS 9 FVOCI treatment and used cost only as a supportable estimate of fair value under IFRS 9.B5.2.3, in which case the treatment may be defensible if properly documented.
  9. Based on the facts currently provided, the stronger view is that the 2023 management decision selected IFRS 9 FVOCI treatment rather than the IAS 27.10 cost method. If this is confirmed, the use of cost in the 2023 and 2024 financial statements should be analysed as a potential prior period error under IAS 8, unless the Company can demonstrate that cost was used merely as an approximation of fair value under IFRS 9.B5.2.3.
  10. If no such fair value assessment was made, and the audited financial statements merely stated that the Company applied the cost method, that disclosure does not convert the treatment into an IFRS-compliant measurement basis. Disclosure of an incorrect accounting treatment does not cure the accounting error.
  11. The error analysis then moves to IAS 8. IAS 8.5 (term 5) defines prior period errors as omissions from, and misstatements in, financial statements for prior periods arising from failure to use, or misuse of, reliable information that was available when those financial statements were authorised for issue and could reasonably have been obtained and taken into account. The same paragraph includes mistakes in applying accounting policies, oversights and misinterpretations of facts.
  12. If the 2023 FVOCI election was available to the Company and should have been applied, the Company’s use of cost in 2023 and 2024 is capable of being a prior period error within IAS 8.5. It would be a mistake in applying the Company’s accounting policy and IFRS 9 classification and measurement requirements.
  13. IAS 8.42 requires material prior period errors to be corrected retrospectively in the first financial statements authorised for issue after discovery. The correction is made by restating the comparative amounts for the prior period presented in which the error occurred, or, if the error occurred before the earliest prior period presented, by restating the opening balances of assets, liabilities and equity for the earliest prior period presented.
  14. For financial reporting purposes, this means that the 2025 financial statements should not present the matter as a new accounting policy adopted in 2025. If the FVOCI election was validly made in 2023, the correct analysis is that the Company is correcting a prior failure to apply the treatment that should have applied from initial recognition.
  15. The Corporate Tax consequences arise because UAE Corporate Tax is built on the financial statements. The Corporate Tax Law uses Accounting Income as the starting point for determining Taxable Income. The FTA guidance on determination of taxable income follows the same approach: the accounting net profit or loss from the financial statements is taken as the starting point and then adjusted under Article 20(2) of the Corporate Tax Law.
  16. This means that the accounting correction cannot be treated as a purely book-keeping issue. If the asset should have been carried at fair value, the statements of financial position, profit and loss and other comprehensive income for 2023 and 2024 were different from what they should have been. Those differences may affect the Corporate Tax opening position and the computation of taxable income in later periods.
  17. The 31 December 2023 balance is particularly important. Assuming the Company’s first UAE Corporate Tax period starts on 1 January 2024, the closing balance sheet as at 31 December 2023 becomes the opening balance sheet for Corporate Tax purposes.[1] The corrected amount of the relevant equity instruments at that date should therefore represent the starting point for determining subsequent taxable movements.
  18. The point may be illustrated as follows. Suppose the Company acquired equity instruments in 2023 for AED 10 million. By 31 December 2023, their fair value was AED 14 million. By 31 December 2024, their fair value was AED 16 million. If the Company incorrectly carried the instruments at cost, the accounts would show AED 10 million both at 31 December 2023 and at 31 December 2024. The accounts would not distinguish the AED 4 million pre-Corporate Tax increase from the AED 2 million movement during the first Corporate Tax period.[2]
  19. If the error is corrected, the 31 December 2023 balance should be AED 14 million, with the corresponding fair value movement recognised in OCI FVOCI reserve, assuming the FVOCI election was valid. The 2024 movement is then measured from AED 14 million to AED 16 million. This approach protects the integrity of the Corporate Tax opening balance because it separates the pre-tax-period fair value movement from the movement arising during the Corporate Tax period.
  20. The same point applies even if the 2025 financial statements formally present only 2024 as the comparative period. For IAS 8 purposes, the earliest comparative period presented may be 2024. However, for Corporate Tax purposes, the Company still needs a defensible opening balance as at 1 January 2024, which is derived from the corrected 31 December 2023 closing balance. Therefore, the corrected 2023 closing data should be introduced into the comparative restatement working papers and, where appropriate, into the explanatory note.
  21. Therefore, it makes sense to prepare a specific 31 December 2023 reconciliation showing:
    1. the carrying amount originally reported at cost;
    2. the corrected fair value under FVOCI;
    3. the difference recognised in OCI/FVOCI reserve;
    4. the consequential opening balance as at 1 January 2024; and
    5. the movement from the corrected opening balance to the 31 December 2024 balance.
  22. This reconciliation is not merely an accounting exercise. It is protective Corporate Tax evidence. If the Company later disposes of the equity instruments, or if questions arise regarding unrealised gains, OCI movements or opening balances, the Company will need to demonstrate which part of the value increase arose before the first Corporate Tax period and which part arose afterwards.
  23. The treatment of unrealised gains and losses also requires attention. Under Article 23(3) of Corporate Tax Law, realised and unrealised gains and losses reported in the financial statements are generally taken into account in determining Taxable Income, unless the Taxable Person elects to use the realisation basis. In addition, gains or losses reported outside the income statement, including in other comprehensive income, may still need to be considered for Corporate Tax purposes.[3]
  24. Therefore, if the Company’s equity instruments are measured at FVOCI, fair value movements recognised in OCI cannot be ignored merely because they do not appear in the profit and loss account. The Corporate Tax analysis must consider whether those OCI movements enter Taxable Income, whether a realisation-basis election has been made, and whether any exemption or other adjustment applies.
  25. If the Company elected to use the realisation basis in its first Tax Period, unrealised gains and losses on assets subject to fair value accounting may generally be disregarded until realisation, depending on the scope of the election. This may defer the Corporate Tax effect of the fair value movements. However, even under the realisation basis, the corrected opening balance remains important, because it determines the baseline from which future realised gains or losses are measured.
  26. The next issue is transitional relief. The Corporate Tax transitional rules were introduced to prevent pre-Corporate Tax gains from being taxed when certain assets or liabilities owned before the first Tax Period are later disposed of. For financial assets and financial liabilities, the transitional rules may allow a Taxable Person to exclude gains or losses related to periods before the first Tax Period.[4]
  27. However, this relief is not generally available for every financial asset. Article 4(1)(b) of Ministerial Decision 134 sets out that, under the transitional rules, Taxable Persons with financial assets, owned before the first Tax Period and recorded on historical cost basis, may elect to adjust their Taxable Income to exclude gains or losses related to periods before the first Tax Period. Therefore, this election can only be made for the relevant assets or liabilities measured on the historical cost basis.
  28. This qualification is central. If the Company corrects the accounting treatment from cost to FVOCI, the relevant equity instruments are no longer recorded on a historical cost basis. They are recorded at fair value. Therefore, the specific transitional relief for qualifying financial assets should not be available for those instruments.
  29. This should not be treated as a contradiction. The transitional relief and the corrected FVOCI opening balance solve a similar timing concern through different mechanisms. The transitional relief protects pre-Corporate Tax gains for certain historical-cost assets by making an adjustment on disposal. By contrast, fair value accounting already brings the pre-Corporate Tax value into the opening balance sheet. The pre-Corporate Tax uplift is therefore protected by the corrected opening value, provided that the correction is properly documented and accepted as the IFRS-compliant position.
  30. In simple terms, the Company should not claim both positions at the same time. If the instruments are correctly measured at FVOCI, the Company should not also rely on a transitional relief designed for financial assets recorded on historical cost basis. Instead, the Company should protect its position through the corrected 31 December 2023 fair value, the IAS 8 restatement analysis, and a clear Corporate Tax reconciliation.
  31. The favourable position is therefore as follows. The Company should correct the accounting error under IAS 8, if material and if retrospective restatement is practicable. It should determine the fair value of the instruments as at initial recognition, 31 December 2023, 31 December 2024 and subsequent relevant dates. It should include the 31 December 2023 corrected fair value in the restatement package, even if 2023 is not a formal comparative year in the 2025 financial statements. It should use this corrected amount as the Corporate Tax opening balance support.
  32. The Company should also prepare a short tax memorandum explaining that the transitional relief for qualifying financial assets is not relied upon because the corrected accounting treatment is not historical cost. The memorandum should instead explain that the corrected opening balance gives effect to the appropriate IFRS position and prevents the pre-Corporate Tax value movement from being misallocated to the Corporate Tax period.
  33. This approach is preferable to leaving the 2023 closing data uncorrected or undocumented. If the Company merely corrects 2024 comparatives without explaining the 31 December 2023 position, the tax file may contain an evidentiary gap. The FTA may then ask why the 2024 opening balance differs from the audited 2023 closing balance, how the pre-Corporate Tax fair value movement was determined, and why the Company did not treat the later disposal gain as arising from the original cost base.
  34. In our view, the Company should not accept that evidentiary gap. The 2023 closing balance is the foundation for the Corporate Tax transition. If that foundation was incorrect because the asset was carried at cost instead of FVOCI, the correction should be made visible in the file. It should not be hidden merely because 2023 may not be a formal comparative period in the 2025 financial statements.
  35. Finally, the Company should ensure that the 2023 management decision is sufficiently robust to evidence a valid FVOCI election under IFRS 9. If the decision was not made at initial recognition, or if it did not identify the relevant instruments or class of instruments, the Company may not be able to rely on FVOCI treatment retrospectively. In that case, a separate IFRS 9 analysis would be required, and the default measurement category may be fair value through profit or loss rather than FVOCI.

Conclusion

  1. Subject to confirmation that the 2023 management decision constituted a valid IFRS 9 FVOCI election at initial recognition, the Company should treat the use of cost in 2023 and 2024 as a prior period error under IAS 8 and correct it retrospectively.
  2. For UAE Corporate Tax purposes, the critical point is the 31 December 2023 corrected closing balance. This balance is the bridge into the first Corporate Tax period. It should be determined, documented and introduced into the comparative/restatement analysis, even if 2023 is not formally presented as a comparative period in the 2025 financial statements.
  3. The Company should not rely on the transitional relief for qualifying financial assets if, after correction, the assets are measured at FVOCI rather than historical cost. The transitional relief is for assets recorded on historical cost basis. In the present case, the better protection is not the transitional relief election but the corrected IFRS opening value.
  4. Accordingly, we recommend that the Company prepare:
    1. an IAS 8 restatement note;
    2. a fair value valuation file for 31 December 2023 and 31 December 2024;
    3. a Corporate Tax opening balance reconciliation as at 1 January 2024; and
    4. a tax memorandum explaining why the transitional relief for historical-cost financial assets is not applicable and why the corrected 2023 closing value should be used as the tax-protective opening value.

The disclaimer

Pursuant to the MoF’s press-release issued on 19 May 2023 “a number of posts circulating on social media and other platforms that are issued by private parties, contain inaccurate and unreliable interpretations and analyses of Corporate Tax”.

The Ministry issued a reminder that official sources of information on Federal Taxes in the UAE are the MoF and FTA only. Therefore, analyses that are not based on official publications by the MoF and FTA, or have not been commissioned by them, are unreliable and may contain misleading interpretations of the law. See the full press release here.

You should factor this in when dealing with this article as well. It is not commissioned by the MoF or FTA. The interpretation, conclusions, proposals, surmises, guesswork, etc., it comprises have the status of the author’s opinion only. Furthermore, it is not legal or tax advice. Like any human job, it may contain inaccuracies and mistakes that we have tried my best to avoid. If you find any inaccuracies or errors, please let us know so that we can make corrections.

[1] Corporate Tax Law, Art. 61(1).

[2] This case study does not analyse whether the revaluation gains may be excluded from Taxable Income under the Participation Exemption. This opportunity requires a separate analysis.

[3] Ministerial Decicion No. 134 of 29 May 2023, Article 2(1)

[4] Ministerial Decision No. 120 of 16 May 2023, Article 4.